SANOFI-AVENTIS (EPA:SAN) Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer
Directive transparence : information réglementée
05/08/2021 12:00
01/06/2023 07:30
01/06/2023 07:30
21/05/2023 20:17
21/05/2023 20:17
17/05/2023 22:01
17/05/2023 22:01
12/05/2023 10:50
04/05/2023 08:00
04/05/2023 08:00
27/04/2023 14:40